novartis ag-sponsored adr
(NVS:New York Consolidated)
Transactions by NOVARTIS AG-SPONSORED ADR (NVS) in the last 6 months
Aduro BioTech, Inc. announced that it has received $25 million in a round of funding from new investor Novartis AG on March 30, 2015. As a result of the transaction, the investor has acquired 2.7% stake in the company. The investor has also committed to invest another $25 million at a future date,
GlaxoSmithKline plc (LSE:GSK) acquired 4.96% stake in Valneva SE (ENXTPA:VLA) from Novartis AG (SWX:NOVN) on March 3, 2015.
Caribou Biosciences, Inc. announced that it has received $11.55 in its series A round of equity funding from Novartis AG on January 7, 2015. The transaction included participation from Fidelity Biosciences, Mission Bay Capital, 5 Prime Ventures, an undisclosed strategic partner, and Jennifer Doudna, co-founder of the company. As a part of transaction, Robert Weisskoff of Fidelity Biosciences joined the company’s board of directors.
Mission Bay Capital LLC
|Gilead Sciences Inc||$115.04 USD||-0.97|
|Johnson & Johnson||$98.44 USD||-0.03|
|Nestle SA||SFr.68.60 CHF||-0.40|
|Pfizer Inc||$33.37 USD||-0.32|
|Roche Holding AG||SFr.265.10 CHF||-1.30|
|View Industry Companies|